Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Comcast Corporation (CMCSA) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Comcast CorporationTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Comcast Corporation vs Inovio Pharmaceuticals Inc — how do they compare? Comcast Corporation trades at $25.18 (market cap $91.02B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: Comcast Corporation is far larger — about 1158.8× Inovio Pharmaceuticals Inc's market cap, and Comcast Corporation pays a 5.15% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CMCSAINO
Market Cap
$91.02B$78.55M
Sector
MediaHealth
52-Week High
$32.50$2.87
52-Week Low
$21.92$0.66
Enterprise Value
$173.74B$49.56M
Dividend Yield
5.15%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Comcast Corporation

CMCSA trades at $25.185, down slightly by 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI levels. The company shows strong fundamentals with a low P/E of 8.22, consistent earnings beats in recent quarters, and robust cash flow generation of $33.64 billion from operations in 2025. Recent news highlights expansion of high-speed internet services and strategic initiatives like the NBCUniversal spinoff.

The outlook for CMCSA is positive, supported by attractive valuation, steady dividend payments, and growth in wireless and streaming. Key risks include competitive pressures in media and broadband, execution of the spinoff, and macroeconomic sensitivity. Analyst consensus is bullish with a $27.78 price target, implying potential upside from current levels.

Inovio Pharmaceuticals Inc

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Comcast Corporation

Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.

Read more on CMCSA

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO